Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Insperity, Inc. (NSP)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 21, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Insperity, Inc. ("Insperity" or the "Company") (NYSE: NSP) common stock between February 11, 2019, and February 11, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Insperity investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/insperity-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [e-mail] to learn more about your rights.

On February 11, 2020, after the market closed, Insperity issued a press release announcing its fourth quarter and full year 2019 financial results. Therein, Insperity disclosed that “[t]he average profit per [worksite employee] per month declined from $272 in 2018 to $259 in 2019 on a higher than expected benefits cost trend due to elevated large healthcare claim activity.” Additionally, the Company reported that it had “recently added a new feature” in its health plan so that, beginning in 2020, Insperity will not have financial responsibility for any amount of a participant’s annual claim costs that exceed $1 million.

On this news, Insperity’s share price fell $17.44 per share, or over 19%, to close at $71.64 per share on February 12, 2020, at unusually heavy trading volume.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company had failed to negotiate appropriate rates with its customers for employee benefit plans and did not adequately disclose the risk of large medical claims from these plans; (2) that Insperity was experiencing an adverse trend of large medical claims; (3) that as a mitigating measure, the Company would be forced to increase the cost of its employee benefit plans, causing stunted customer growth and reduced customer retention; and (4) that the foregoing issues were reasonably likely to, and would, materially impact Insperity’s financial results.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Insperity common stock during the class period, you may move the Court no later than September 21, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [e-mail], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.